We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $429M
1-Year Est. Return 52.52%
This Fund
S&P 500
This Quarter Est. Return
+23.54%
1 Year Est. Return
+52.52%
3 Year Est. Return
+172.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$66.7M
Cap. Flow
+$19.4M
Cap. Flow %
4.52%
Top 10 Hldgs %
7.64%
Holding
517
New
67
Increased
228
Reduced
168
Closed
54

Top Buys

Rank Stock Value
1
DVN icon
Devon Energy
DVN
+$3.47M
2
DDOG icon
Datadog
DDOG
+$2.53M
3
MRVL icon
Marvell Technology
MRVL
+$2.28M
4
WDC icon
Western Digital
WDC
+$2.19M
5
NTAP icon
NetApp
NTAP
+$2.17M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$2.17M
2
LIN icon
Linde
LIN
+$2.08M
3
HSY icon
Hershey
HSY
+$2.06M
4
LYV icon
Live Nation Entertainment
LYV
+$1.97M
5
KO icon
Coca-Cola
KO
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 38.77%
2 Technology 15.15%
3 Financials 13.21%
4 Industrials 12.74%
5 Consumer Discretionary 5.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FDUS icon
251
Fidus Investment
FDUS
$736M
$420K 0.1%
22,003
-8,440
-28% -$157K
VOR icon
252
Vor Biopharma
VOR
$1.31B
$419K 0.1%
+22,785
New +$345K
ZBIO
253
Zenas BioPharma
ZBIO
$2.08B
$419K 0.1%
16,525
+9,808
+146% +$195K
MANE
254
Veradermics Inc
MANE
$4.3B
$419K 0.1%
+3,406
New +$319K
GHRS icon
255
GH Research
GHRS
$1.9B
$416K 0.1%
15,492
-5,428
-26% -$113K
OLMA icon
256
Olema Pharmaceuticals
OLMA
$850M
$415K 0.1%
33,150
+24,900
+302% +$334K
RLAY icon
257
Relay Therapeutics
RLAY
$4.15B
$413K 0.1%
22,094
-11,863
-35% -$172K
PRAX icon
258
Praxis Precision Medicines
PRAX
$8.68B
$411K 0.1%
1,227
+214
+21% +$67.7K
BCSF icon
259
Bain Capital Specialty
BCSF
$721M
$411K 0.1%
32,810
-9,678
-23% -$126K
VERA icon
260
Vera Therapeutics
VERA
$2.31B
$410K 0.1%
9,550
+4,076
+74% +$152K
CRVS icon
261
Corvus Pharmaceuticals
CRVS
$1.06B
$410K 0.1%
27,427
-5,152
-16% -$71.5K
AVTX icon
262
Avalo Therapeutics
AVTX
$877M
$410K 0.1%
+22,168
New +$350K
DMRA
263
Damora Therapeutics
DMRA
$1.51B
$410K 0.1%
+15,746
New +$381K
OCS icon
264
Oculis Holding
OCS
$536M
$409K 0.1%
+29,504
New +$670K
GPCR icon
265
Structure Therapeutics
GPCR
$2.65B
$409K 0.1%
7,622
+3,557
+88% +$157K
LXRX icon
266
Lexicon Pharmaceuticals
LXRX
$899M
$409K 0.1%
+170,415
New +$332K
REPL icon
267
Replimune Group
REPL
$1.21B
$408K 0.1%
36,846
+10,060
+38% +$61.5K
CTMX icon
268
CytomX Therapeutics
CTMX
$612M
$408K 0.1%
108,703
+43,623
+67% +$167K
SRRK icon
269
Scholar Rock
SRRK
$6.06B
$407K 0.09%
7,406
+1,590
+27% +$76.8K
PROK icon
270
ProKidney
PROK
$382M
$407K 0.09%
199,510
+76,122
+62% +$139K
RCKT icon
271
Rocket Pharmaceuticals
RCKT
$386M
$407K 0.09%
118,981
+38,543
+48% +$128K
MAZE
272
Maze Therapeutics
MAZE
$1.37B
$406K 0.09%
13,605
+6,589
+94% +$173K
HTGC icon
273
Hercules Capital
HTGC
$3.32B
$403K 0.09%
25,577
-9,079
-26% -$141K
AMLX icon
274
Amylyx Pharmaceuticals
AMLX
$3.65B
$403K 0.09%
22,426
+1,611
+8% +$24.9K
GBDC icon
275
Golub Capital BDC
GBDC
$3.25B
$403K 0.09%
31,259
-17,106
-35% -$223K
9 10
11
12 13

Similar funds

MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return
PG
Prostatis Group Hanover, Maryland $429M AUM 26.55% 1-Year Est. Return
LFGO
Legacy Financial Group (Oklahoma) Tulsa, Oklahoma $429M AUM 21.51% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $430M AUM 17.41% 1-Year Est. Return
RS
Rakuten Securities Tokyo, Japan $430M AUM 189.97% 1-Year Est. Return
T
TrueFG Cedar Park, Texas $428M AUM 21.6% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Virtus Investment Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, Virtus Investment Advisers held 517 positions worth $429M, up 18% from $363M the previous quarter. Its ten largest holdings account for 7.6% of the portfolio.

Virtus Investment Advisers deployed $19.4M of net new capital in Q2 2026, opening 67 new positions and adding to 228 existing holdings. Its largest new stake was Devon Energy: 74,863 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was ImmunityBio, an estimated $1.47M trimmed.

  • Virtus Investment Advisers's largest Q2 2026 buy was Devon Energy: 74,863 shares worth $3.09M.
  • Virtus Investment Advisers added most to Omeros in Q2 2026, an estimated $1.26M increase.
  • Virtus Investment Advisers's biggest Q2 2026 reduction was ImmunityBio, cutting an estimated $1.47M.
  • Virtus Investment Advisers fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $2.17M.
  • Virtus Investment Advisers's ten largest holdings make up 7.6% of its $429M portfolio in Q2 2026.
  • Virtus Investment Advisers opened 67 new positions and closed 54 in Q2 2026.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $429M.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.